A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy

High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study

(2015) Maurizio Musso et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation

(2015) Nina Shah et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants

(2015) J R Passweg et al.   BONE MARROW TRANSPLANTATION

A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT

(2015) W I Bensinger et al.   BONE MARROW TRANSPLANTATION

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study

(2014) Massimo Martino et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The future of autologous stem cell transplantation in myeloma

(2014) F. van Rhee et al.   BLOOD

Autologous stem cell transplantation in multiple myeloma is not dead but alive and well

(2014) Massimo Martino et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

(2014) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine for the treatment of multiple myeloma in first-line and relapsed–refractory settings: a review of clinical trial data

(2014) Antonio Palumbo et al.   LEUKEMIA & LYMPHOMA

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

(2014) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

European Perspective on Multiple Myeloma Treatment Strategies in 2014

(2014) H. Ludwig et al.   ONCOLOGIST

A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma

(2013) Tomer M. Mark et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma

(2013) Massimo Martino et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

(2012) Margarita Blanes et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

(2012) M. Cavo et al.   BLOOD

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

(2011) K. Neben et al.   BLOOD

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

(2011) G. Visani et al.   BLOOD

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

(2011) M. Cavo et al.   BLOOD

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

(2010) J. J. Lahuerta et al.   HAEMATOLOGICA

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)

(2009) M. Roussel et al.   BLOOD

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

(2008) L. M. Leoni et al.   CLINICAL CANCER RESEARCH